Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.59 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CDK8 | P49336 | 1/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5685284 | 0.93 | CALM1 (0.57) | CYP4F2CYP4A11LMNASMN1; SMN2CA12 | |
| SCHEMBL11733932 | 0.91 | LMNA (0.55) | LMNASMN1; SMN2CA12CA1CA2 | |
| SCHEMBL8912630 | 0.89 | CYP4F2 (0.58) | CYP4F2CYP4A11LMNASMN1; SMN2CA12 | |
| SCHEMBL8984891 | 0.89 | CYP4F2 (0.58) | CYP4F2CYP4A11LMNASMN1; SMN2CA12 | |
| SCHEMBL2632416 | 0.89 | CYP4F2 (0.58) | CYP4F2CYP4A11LMNASMN1; SMN2CA12 | |
| SCHEMBL5688167 | 0.89 | CYP4F2 (0.51) | CYP4F2CYP4A11LMNASMN1; SMN2CA12 | |
| SCHEMBL5688330 | 0.89 | HDAC1 (0.56) | CYP4F2CYP4A11LMNASMN1; SMN2DRD2 | |
| Dihydroferulic Acid Ethyl Ester SCHEMBL356300 | 0.88 | ALOX5 (0.67) | CYP4F2CYP4A11LMNALTA4HCYP1A2 | |
| SCHEMBL491225 | 0.88 | CYP19A1 (0.60) | CYP4F2CYP4A11LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL2432179 | 0.88 | CYP4F2 (0.56) | CYP4F2CYP4A11LMNASMN1; SMN2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3761950-B1 | BIOISPIRED PROTEASOME ACTIVATORS WITH ANTIAGEING ACTIVITY | IOULIA & IRENE TSETI PHARMACEUTICAL LABORATORIES IND AND COMMERCIAL S A (GR) | 2025-04-09 | — | — | EP | disclosed |
| EP-3761950-A1 | BIOISPIRED PROTEASOME ACTIVATORS WITH ANTIAGEING ACTIVITY | IOULIA AND IRENE TSETI Pharmaceutical Laboratories S.A. (GR) | 2021-01-13 | — | — | EP | disclosed |
| WO-2019171088-A1 | BIOISPIRED PROTEASOME ACTIVATORS WITH ANTIAGEING ACTIVITY | NATIONAL HELLENIC RESEARCH FOUNDATION (GR) | 2019-09-12 | — | — | WO | disclosed |
| WO-2019171088-A1 | BIOISPIRED PROTEASOME ACTIVATORS WITH ANTIAGEING ACTIVITY | NATIONAL HELLENIC RESEARCH FOUNDATION (GR) | 2019-09-12 | — | — | WO | disclosed |
| US-8268293-B2 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| CN-101163659-B | Antioxidants | MERCK PATENT GMBH | 2012-09-05 | — | — | CN | disclosed |
| US-8106233-B2 | Applying di-2-ethylhexyl 4-hydroxy-3,5-dimethoxy-benzylmalonate; protective action against UV rays, oxidative stress on body cells, counters skin ageing | MERCK PATENT GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| EP-2229377-A1 | 5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS | Wyeth LLC (US) | 2010-09-22 | — | — | EP | disclosed |
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| US-4474692-A | L-Alanyl-N-(indan-2-yl)glycine, its esters and salts thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1984-10-02 | — | — | US | disclosed |
| EP-0051391-B1 | BICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1984-09-05 | — | — | EP | disclosed |
| EP-0057998-B1 | ALICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1984-08-08 | — | — | EP | disclosed |
| EP-0057998-A1 | Alicyclic compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1982-08-18 | — | — | EP | disclosed |
| EP-0054174-A2 | Topical cosmetic formulations for the treatment of very greasy hair and seborrhoeic skin | Henkel Kommanditgesellschaft auf Aktien (DE) | 1982-06-23 | — | — | EP | disclosed |
| EP-0054174-A2 | Topical cosmetic formulations for the treatment of very greasy hair and seborrhoeic skin | Henkel Kommanditgesellschaft auf Aktien (DE) | 1982-06-23 | — | — | EP | disclosed |
| EP-0051391-A1 | Bicyclic compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1982-05-12 | — | — | EP | disclosed |
| US-4218452-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-08-19 | — | — | US | disclosed |
| US-4159329-A | BLOCKING AGENTS, ANTAGONISTS, ANTIHISTAMINES | SMITHKLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-06-26 | — | — | US | disclosed |
| US-4145546-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | NR3C1, NR3C2, NR0B1 | CYP4F2 244/4885CYP4A11 16/4885LMNA 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.